The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Clinical trial NCT01790126 · COMPLETED
Trial details
- NCT number
- NCT01790126
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-04
- Primary completion
- 2019-03-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.